| All adalimumab | Adalimumab non-progressors† | Adalimumab progressors† | All placebo/adalimumab‡ | Placebo/adalimumab‡ non-progressors† | Placebo/adalimumab‡ progressors† | |
| N | 115 | 103 | 12 | 128 | 90 | 38 |
| Baseline mTSS, mean | 22.3 | 16.1 | 74.9 | 21.9 | 14.9 | 38.5 |
| Changes in mTSS, mean (SD) | ||||||
| Baseline to week 24 | −0.1 (1.20) | −0.3 (0.93) | 1.7 (1.62) | 0.8 (2.42) | −0.1 (0.51) | 3.0 (3.56) |
| Baseline to week 48 | 0.1 (1.95) | −0.3 (0.90) | 2.9 (4.73) | 0.8 (4.23) | −0.3 (2.73) | 3.3 (5.85) |
| Baseline to week 144 | 0.5 (4.20) | −0.1 (1.75) | 6.2 (10.77) | 0.9 (6.36) | 0.1 (1.72) | 2.9 (11.23) |
| Week 24 to week 144 | 0.6 (3.62) | 0.2 (1.88) | 4.4 (9.26) | 0.1 (5.71) | 0.2 (1.72) | −0.1 (10.23) |
*Patients included in this analysis are those who had a radiographic measure at baseline, week 24, week 48 and at week 96 or week 144. Data are imputed; for patients who did not have a week 144 modified total Sharp score (mTSS), the week 96 mTSS was used.
†Progression was defined as a mean change in mTSS >0.5 from baseline to week 24.
‡Patients who were randomly assigned to receive placebo during the double-blind phase of the study began receiving open-label adalimumab 40 mg every other week starting at week 24.